Article info

Download PDFPDF
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Authors

  1. Correspondence to : Dr André J Scheen, Division of Diabetes, Nutrition & Metabolic Disorders and Clinical Pharmacology Unit (CIRM), CHU Sart Tilman (B35), University of Liège, Liège B-4000, Belgium; andre.scheen{at}chu.ulg.ac.be
View Full Text

Citation

Scheen AJ
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Publication history

  • First published February 3, 2017.
Online issue publication 
March 23, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.